Takeda and fruquintinib
Hutchmed
Which company did Takeda license fruquintinib from for ex-China, Hong Kong and Macau use?
Patient profile, tumour status and potential treatment
What three categories are considered at a patient with mCRC’s first assessment
VEGFR-1, -2 and -3
What is are the molecular targets of fruquintinib
FRUZAQLA and ELUNATE
What are the brand names of fruquintinib ex-China and in China?
FOLFOX and FOLFIRI
Which chemotherapy options do patients with mCRC generally switch between in 1L and 2L?
Prior treatment with a VEGFR inhibitor
What was not permitted in the trial eligibility criteria of FRESCO?
Previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy
What is the base assumption for Takeda about pre-treatment that will be required as part of fruquintinib’s label?
England, Poland, Canada
What are three of the countries in which bevacizumab is not reimbursed?
9.30 months and 3.71 months
What was the median overall survival and median progression-free survival with fruquintinib in the FRESCO trial?
January 23 2023
When did Takeda announce that it was acquiring fruquintinib for ex-China use from Hutchmed?
35.2%
What is the proportion of patients who are predicted to have a clinical benefit after treatment with fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy?
55.5%
What was the DCR for patients who received fruquintinib in FRESCO-2
June 15 2023
When did Takeda announce the marketing authorization application of fruquintinib had been validated by the EMA?
Chemotherapy doublet + anti-EGFR
Which treatment combination are patients with RAS/BRAF-wt, left-sided mCRC recommended at 1L?
19.3% fruquintinib versus 2.6% placebo
What proportion of patients in FRESCO-2 had HFS (any grade) as an AESI?